{"id":"empasiprubart-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immunogenicity"}]},"_chembl":{"chemblId":"CHEMBL5314673","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking FcRn-mediated recycling, empasiprubart increases IgG catabolism and prolongs circulating antibody half-lives, which can amplify the effects of endogenous or co-administered IgG-based therapeutics. This mechanism is designed to enhance immune responses in autoimmune and inflammatory conditions where increased antibody persistence is therapeutically beneficial.","oneSentence":"Empasiprubart is a FcRn (neonatal Fc receptor) antagonist that reduces the recycling and extends the half-life of IgG antibodies, enhancing their therapeutic activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:43.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized myasthenia gravis (gMG)"},{"name":"Other autoimmune conditions (under investigation)"}]},"trialDetails":[{"nctId":"NCT07091630","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP","status":"RECRUITING","sponsor":"argenx","startDate":"2025-09-16","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":160},{"nctId":"NCT07294170","phase":"","title":"ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis","status":"RECRUITING","sponsor":"argenx","startDate":"2025-12-19","conditions":"Myasthenia Gravis, MG, gMG","enrollment":70},{"nctId":"NCT07284420","phase":"PHASE2","title":"ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","status":"RECRUITING","sponsor":"argenx","startDate":"2025-12-19","conditions":"AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG","enrollment":70},{"nctId":"NCT06284954","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-08-20","conditions":"Dermatomyositis, Myositis","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ARGX-117"],"phase":"phase_3","status":"active","brandName":"Empasiprubart IV","genericName":"Empasiprubart IV","companyName":"argenx","companyId":"argenx","modality":"Biologic","firstApprovalDate":"","aiSummary":"Empasiprubart IV is an antibody used in clinical trials to study its safety and efficacy in treating various conditions, including dermatomyositis, myositis, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, and CIDP. It is administered intravenously as part of a phase 2 clinical trial.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}